BRIEF published on 11/29/2024 at 07:36, 6 days 4 hours ago Evotec annonce le départ de son directeur opérationnel et une restructuration interne Changement De Direction Evotec Médicaments Départ Du COO Restructuration Interne
BRIEF published on 11/29/2024 at 07:36, 6 days 4 hours ago Evotec Announces COO Departure and Internal Restructuring Pharmaceuticals Management Change Evotec COO Departure Internal Restructuring
PRESS RELEASE published on 11/29/2024 at 07:31, 6 days 4 hours ago Evotec announces change in Management Board Evotec SE announces the departure of Chief Operating Officer Dr Craig Johnstone effective December 31, 2024, with internal distribution of responsibilities. Management praises Johnstone's contribution and commitment Global Operations Chief Operating Officer Evotec SE Management Board Dr Craig Johnstone
BRIEF published on 11/22/2024 at 17:00, 12 days 18 hours ago Evotec SE commente le retrait de l'offre d'Halozyme Evotec SE Valeur Actionnariale Proposition D'acquisition Thérapeutique Halozyme Offre Sans Engagement
BRIEF published on 11/22/2024 at 17:00, 12 days 18 hours ago Evotec SE Comments on Withdrawal of Halozyme's Offer Shareholder Value Evotec SE Acquisition Proposal Halozyme Therapeutics Non-binding Offer
PRESS RELEASE published on 11/22/2024 at 16:55, 12 days 18 hours ago EQS-Adhoc: Comment on withdrawn non-binding offer Evotec SE acknowledges withdrawal of non-binding offer by Halozyme Therapeutics Inc. for acquisition. Management reiterates confidence in standalone strategy Acquisition Evotec SE Halozyme Therapeutics Inc. Withdrawn Offer Standalone Strategy
BRIEF published on 11/14/2024 at 22:56, 20 days 12 hours ago Evotec SE Responds to Interest from Halozyme Evotec SE Takeover Halozyme Therapeutics Expression Of Interest EUR 11 Per Share
BRIEF published on 11/14/2024 at 22:56, 20 days 12 hours ago Evotec SE répond à l'intérêt d'Halozyme Evotec SE Reprendre Thérapeutique Halozyme Manifestation D'intérêt 11 EUR Par Action
PRESS RELEASE published on 11/14/2024 at 22:51, 20 days 12 hours ago EQS-Adhoc: Comment on media report Evotec SE receives non-binding expression of interest from Halozyme Therapeutics Inc. for a takeover offer of EUR 11.00 per share Evotec SE Takeover Offer Expression Of Interest Halozyme Therapeutics Inc. EUR 11.00 Per Share
BRIEF published on 11/06/2024 at 07:05, 29 days 4 hours ago Evotec SE Reports Strategic Progress and Revenue Growth Amid Challenges Strategic Partnerships 2024 Forecasts Biologics Growth Evotec Financial Results Priority Reset Initiative
Published on 12/05/2024 at 11:00, 48 minutes ago Kingfisher Signs Definitive Agreement to Acquire the Ball Creek West (BAM) Project
Published on 12/05/2024 at 00:00, 11 hours 48 minutes ago Electric Royalties Closes Acquisition of 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 12/04/2024 at 23:25, 12 hours 23 minutes ago Supreme Critical Metals Inc. Update on Project, Debt Settlements and Cancellations of Incentive Stock Options
Published on 12/04/2024 at 23:00, 12 hours 48 minutes ago Gold Terra Announces Closing of Non-Flow-Through Portion of the Non-Brokered Private Placement
Published on 12/04/2024 at 22:55, 12 hours 53 minutes ago TACACS.net: Strengthening Network Security with Native Active Directory Integration
Published on 12/05/2024 at 11:20, 27 minutes ago Aareal Bank provides €214 million refinancing for the largest outlet centre in northern Germany
Published on 12/05/2024 at 11:15, 33 minutes ago Africa Finance Corporation (AFC)-led Zambia Lobito Rail Project receives boost from Biden visit to Angola
Published on 12/05/2024 at 11:09, 38 minutes ago thyssenkrupp nucera Strengthens Cyber Security With ISO 27001 Certificate
Published on 12/05/2024 at 11:01, 47 minutes ago naoo AG Completes Successful Stock Market Listing in Germany
Published on 12/05/2024 at 10:58, 50 minutes ago Strategic Realignment: USU Accelerates Innovation and Brand Expansion
Published on 12/05/2024 at 08:30, 3 hours 18 minutes ago Capital Market Day: Updating Mersen’s roadmap
Published on 12/05/2024 at 08:30, 3 hours 18 minutes ago Capital Market Day : Actualisation de la feuille de route de Mersen
Published on 12/05/2024 at 08:02, 3 hours 46 minutes ago NFL BIOSCIENCES VALIDE L’INDUSTRIALISATION DE NFL-101 POUR LE SEVRAGE TABAGIQUE
Published on 12/05/2024 at 08:02, 3 hours 46 minutes ago NFL BIOSCIENCES VALIDATES THE INDUSTRIALIZATION OF NFL-101 FOR SMOKING CESSATION
Published on 12/05/2024 at 07:55, 3 hours 53 minutes ago Safran 2024 Capital Markets Day (CMD’24): Safran is poised to deliver a further period of profitable growth
